Coagulopathy of Immunodermatologic Diseases
ConditionAutoimmune Bullous Dermatosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorUniversity of Nebraska
About this trial
This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.
Eligibility criteria
Qualifiers
For the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis
For control group: no diagnosis of immune-mediated skin
For study group: receiving care from one or more of the Principal or Secondary Investigators
Disqualifiers
Unfit to provide consent
P2Y12 inhibitor use in the past 4 weeks
History of internal malignancy prior to enrolling in the study or suspected internal/systemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies)
Major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study
Trial design
Treatments tested in this trial
- Blood Draw
Treatment groups
39 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov